Back

Glycemic control and atrial fibrillation: baseline HbA1c predicts risk, early HbA1c change does not

31 August 2026 (11:15 - 12:00)
Organised by: Logo
Congress Presentation Part of: Atrial fibrillation prediction and risk stratification Prevalence and Incidence of Atrial Fibrillation ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Miss Yuval Elhayani

Beer Sheva (Israel)

6 More presentations in this session

Presentation thumbnail
Polygenic risk and echocardiographic markers of left atrial dysfunction improve prediction of incident atrial fibrillation: insights from the akershus cardiac examination (ACE) 1950 Study
Doctor M. Solberg (Gjettum, NO)
Abstract
Presentation thumbnail
Body mass index, weight change, and long-term risk of incident atrial fibrillation in a nationwide cohort
Miss Y. Elhayani (Beer Sheva, IL)
Abstract
Presentation thumbnail
Polygenic risk stratifies atrial fibrillation into biologically distinct prognostic phenotypes
Ms E. Ghanbari (Berlin, DE)
Abstract
Presentation thumbnail
Multimodal prediction of atrial fibrillation following cardiac surgery using clinical and polygenic scores
Doctor G. Jabbour (Montreal, CA)
Abstract
Presentation thumbnail
Multi-national assessment of clinical factors, genetic scores, and electrocardiogram-based artificial intelligence for atrial fibrillation prediction
Doctor S. Kany (Hamburg, DE)
Abstract

Access the full session

Session thumbnail
Atrial fibrillation prediction and risk stratification

The Event

Event poster

ESC Congress 2026

31 August 2026 11:15 CET
You may be interested in
thumbnail
Congress Presentation
Hba1c variability is associated with adverse outcomes in heart failure patients with and without diabetes
21 May 2023
thumbnail
Congress Presentation
Different risk of atrial fibrillation according to the type of cancer: a nationwide population-based study
28 August 2020
thumbnail
Congress Presentation
Differential effect of low-voltage area ablation on atrial tachycardia recurrence in diabetic versus non-diabetic patients with persistent atrial fibrillation: sub-analysis of the SUPPRESS-AF Trial
1 September 2025
thumbnail
Congress Presentation
Serial measurement of biomarkers and the risk of stroke or systemic embolism and bleeding in patients with atrial fibrillation in ENGAGE AF-TIMI 48
29 August 2020

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources